Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of March 2023. The document serves as a transaction notification regarding a purchase of company shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
| Transaction Type | Instrument | Volume | Price per Share | Total Value (Approx.) |
|---|---|---|---|---|
| Purchase | Ordinary Shares (31 pence each) | 2,100 | £13.9884 | £29,375.64 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction executed on March 20, 2023, on the London Stock Exchange (XLON).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a mandatory disclosure of insider trading activity.
Key Facts for Investor Verification
- Insider Identity: Sir Jonathan Symonds, Non-Executive Chair.
- Transaction Nature: Purchase of 2,100 Ordinary Shares.
- Transaction Date: March 20, 2023.
- Execution Venue: London Stock Exchange (XLON).
- Price Point: £13.9884 per share.